Home›Drug Pipeline› Resina Draconis plus conventional therapy improves healing response in diabetic foot ulcers
Resina Draconis plus conventional therapy improves healing response in diabetic foot ulcersResina Draconis may speed healing for diabetic foot ulcers
Frontiers in MedicinePublished August 23, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider Resina Draconis as an adjunct to conventional therapy for diabetic foot ulcers, but interpret results cautiously.
This meta-analysis synthesized randomized controlled trials assessing the adjunctive use of Resina Draconis with conventional therapy for diabetic foot ulcers (DFUs). The analysis included 1,011 patients and focused on overall healing response as the primary outcome, with secondary outcomes of wound-healing time and serum C-reactive protein (CRP) levels.
Pooled results showed a significant improvement in overall healing response (RR = 0.28; 95% CI, 0.20–0.39; P < 0.00001), indicating a favorable effect. Wound-healing time was shortened (MD = -11.66; 95% CI, -21.62 to -1.69; P = 0.02), and serum CRP levels were reduced (MD = -1.99; 95% CI, -2.99 to -0.99; P < 0.0001). No serious adverse events were reported, though adverse events were not reported overall.
The authors note limitations including limited sample sizes and potential publication bias, which warrant cautious interpretation. The analysis did not report follow-up duration or funding sources.
In practice, Resina Draconis may serve as an effective and safe adjunctive therapy for DFUs, potentially enhancing wound healing and reducing systemic inflammation. However, given the limitations, clinicians should consider these findings as preliminary and await further high-quality evidence.
How this fits prior evidence
This meta-analysis extends prior coverage on diabetic foot ulcer management by evaluating a botanical adjunct. It aligns with the finding that placenta-derived products significantly improve healing rates, suggesting other adjunctive therapies may also offer benefits. It contrasts with the narrative review of ADSC-Exos, which lacked efficacy data, by providing quantitative pooled effect sizes. It also complements temperature-guided prevention and debridement strategies by addressing a different therapeutic angle, though it does not directly address microbial dysbiosis.
Living with diabetes can make it incredibly hard for wounds on the feet to heal. These ulcers are serious because they can lead to severe complications. New data suggests that adding a substance called Resina Draconis to standard medical treatments might help patients see better results.
Researchers looked at data from 1,011 patients with diabetic foot ulcers. They found that those who used Resina Draconis alongside their regular care showed a significantly improved healing response compared to those receiving only standard treatment. The study also showed that the time it took for wounds to heal was shortened and levels of C-reactive protein, which is a marker for inflammation in the body, were lower.
While these results are promising, the findings should be viewed with some caution. The researchers noted that the data comes from smaller sample sizes and could be affected by publication bias. However, the evidence suggests Resina Draconis could be a helpful extra tool to help patients heal faster and reduce inflammation.
What this means for you:
Adding Resina Draconis to standard care may speed up healing and lower inflammation in diabetic foot ulcers.
Common questions
How does Resina Draconis help with diabetic foot ulcers?
When added to conventional therapy, Resina Draconis showed a significantly improved overall healing response. It also helped shorten the time it took for wounds to heal and reduced serum C-reactive protein levels, which are markers of inflammation in the body.
Is this treatment safe for patients with foot ulcers?
The study did not report any serious adverse events or specific safety concerns. While it may be an effective and safe addition to standard care, you should always talk to your doctor before starting any new treatment.
How much faster does the wound heal with this treatment?
The study found that adding Resina Draconis to standard therapy shortened the wound-healing time. However, because of limited sample sizes and potential publication bias, these results should be interpreted carefully by medical professionals.
BackgroundResina Draconis, a traditional Chinese herbal medicine with wound‐healing properties, has been increasingly used as an adjunctive treatment for diabetic foot ulcers (DFUs). This systematic review and meta‐analysis aimed to evaluate the efficacy and safety of Resina Draconis in the treatment of DFUs.MethodsFive electronic databases were systematically searched for randomized controlled trials (RCTs) published up to December 2025. Eligible studies compared Resina Draconis combined with conventional therapy versus conventional therapy alone in patients with DFUs. Dichotomous outcomes were expressed as risk ratios (RRs), and continuous outcomes as mean differences (MDs), both with 95% confidence intervals (CIs).ResultsFourteen RCTs involving 1,011 participants were included. The meta‐analysis showed that adjunctive treatment with Resina Draconis significantly improved the overall healing response (RR = 0.28; 95% CI, 0.20–0.39; P < 0.00001), shortened wound‐healing time (MD = −11.66; 95% CI, −21.62 to −1.69; P = 0.02), and reduced serum C‐reactive protein levels (MD = −1.99; 95% CI, −2.99 to −0.99; P < 0.0001). No serious adverse events were reported.Conclusions Resina Draconis may be an effective and safe adjunctive therapy for DFUs, potentially enhancing wound healing and reducing systemic inflammation. However, the findings should be interpreted cautiously because of the limited sample sizes and potential publication bias of the included studies. Further large‐scale, rigorously designed RCTs are needed to confirm these results.Systematic Review RegistrationIdentifier CRD42020189060.
